Cytokine Expression in Sera, Ex Vivo Stimulated Peripheral Blood Mononuclear Cells Culture, and Skin in Psoriasis - Comparison of Patients with and Without Joint Involvement

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The objective of the resarch is to study the cytokine profile of patients with psoriatic arthritis and psoriasis in order to better understand the pathophysiology of the disease and the contribution of cytokines to the presence or absence of joint involvement. This research will compare cytokines levels in sera, in PBMC culture after LPS or CD3/CD28 agonist antibodies, and in skin biopsy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: t
View:

• For psoriasis patients :

‣ Age over 18 years old

⁃ Signed informed consent

⁃ 5 year old psoriasis at least

⁃ At least one skin lesion over 2 cm

⁃ Without any articular symptoms

⁃ Without any DMARDs

⁃ Without anticoagulant treatments or coagulation disease

⁃ With normal articular and enthesis sonography

• For psoriatic arthritis patients :

‣ Age over 18 years old

⁃ Signed informed consent

⁃ Psoriatic arthritis according to CASPAR criteria

⁃ Without any DMARDs

⁃ Without anticoagulant treatments or coagulation disease

⁃ With at least one synovitis at inclusion

• For controls

‣ Age and sex matched with a patient without any rheumatic or dermatologic medical conditions

⁃ No treatment with corticosteroïds or non-steroïdial anti-inflammatory drugsAge over 18 years old

Locations
Other Locations
France
Chu Poitiers
RECRUITING
Poitiers
Contact Information
Primary
Guillaume LARID
rhumatologie@chu-poitiers.fr
+33549444465
Time Frame
Start Date: 2022-08-17
Estimated Completion Date: 2026-08-18
Participants
Target number of participants: 40
Treatments
Experimental: Psoriasis
Experimental: Psoriatic arthritis
Active_comparator: Controls
Related Therapeutic Areas
Sponsors
Leads: Poitiers University Hospital

This content was sourced from clinicaltrials.gov